# Alpha Tau Medical (DRTS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DRTS
## Company Profile
- Ticker: DRTS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel
- Tags: Oncology
## Stock Data
- Close: 13.26 USD
- Market cap: 806610072.68 USD
- Last updated: 2026-08-05
## Business Overview
### Alpha Radiation Oncology Company
Alpha Tau Medical is an Israel-based oncology company developing Alpha DaRT, a single-use, minimally invasive, intratumoral alpha-radiation therapy. Originating at Tel Aviv University, the technology is designed to deliver high-energy alpha particles locally within solid tumors.
### Pancreatic Cancer Evidence
At ASCO, the company presented a pooled analysis from three prospective Phase 1/2 studies in pancreatic ductal adenocarcinoma. The dataset included locally advanced and metastatic disease across first-line post-chemotherapy, second-line, and heavily pretreated settings, with encouraging survival and safety observations.
### Local Treatment Strategy
Alpha DaRT is being developed as a local complement to systemic therapy rather than a replacement. The approach seeks to intensify tumor-directed treatment without adding substantial systemic toxicity to standard chemotherapy.
### Solid Tumor Development Platform
Because Alpha DaRT is implanted directly into tumors, the platform may be evaluated across multiple accessible solid-tumor types. Pancreatic cancer is one active development setting within a broader strategy for localized alpha-particle treatment.
## Why The Stock Is Moving

As of Aug 5, 2026, DRTS closed up 1.38% at $13.26. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of enrollment in the U.S. multicenter IMPACT pancreatic cancer trial is the next identified milestone for Alpha DaRT in combination with first-line chemotherapy.

## Recent News
- 2026-07-21 12:30 EST — [Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success](https://biopharmsignal.com/news/DRTS/alpha-tau-reports-positive-data-demonstrating-100-objective-response-rate-and-18-ca86b4f0) — Source: Alpha Tau Medical
- 2026-07-15 12:30 EST — [Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center](https://biopharmsignal.com/news/DRTS/alpha-tau-successfully-treats-first-immunocompromised-patient-with-recurrent-cut-6fd4ea97) — Source: Alpha Tau Medical
- 2026-06-23 12:30 EST — [Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel](https://biopharmsignal.com/news/DRTS/alpha-tau-successfully-treats-first-recurrent-glioblastoma-patient-outside-of-th-72be30a9) — Source: Alpha Tau Medical
- 2026-06-11 12:30 EST — [Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control](https://biopharmsignal.com/news/DRTS/alpha-tau-receives-fda-clearance-to-complete-enrollment-in-regain-recurrent-glio-3c500481) — Source: Alpha Tau Medical
- 2026-06-03 12:30 EST — [Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients](https://biopharmsignal.com/news/DRTS/alpha-tau-and-tolmar-announce-strategic-collaboration-to-bring-alpha-dart-therap-82e0cf6e) — Source: Alpha Tau Medical